ArticleAmerican journal of translational research2026
Comparison of analgesic and sedative effects of dexmedetomidine and propofol in patients with traumatic brain injury.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the analgesic and sedative efficacy of dexmedetomidine (DEX) compared with propofol in individuals suffering from traumatic brain injury (TBI).
methodsA total of 126 participants with TBI and agitation, who were admitted to Suzhou Ninth Hospital Affiliated to Soochow University from January 2023 to January 2025, were enrolled in this study. According to the sedative agent assigned, these participants were categorized either into Group A (DEX) or Group B (propofol). Vital signs and blood gas measurements of the two cohorts were documented and contrasted before and after treatment. The Behavioral Pain Scale (BPS) and the Richmond Agitation-Sedation Scale (RASS) were employed for evaluation and comparison purposes. The frequencies of adverse reactions, including delirium, elevated blood pressure (BP), reduced BP, and bradycardia (slowed heart rate, HR), were monitored and contrasted between the two cohorts. The analgesic effectiveness of DEX was appraised in traumatic brain injury patients, alongside an evaluation of its consequences on vital signs, blood gas parameters, and safety profile. Records were kept regarding sedative and analgesic maintenance outcomes, sedation-linked adverse occurrences, and cerebral oxygen metabolism indices. Spearman correlation and logistic regression analyses were applied to determine factors influencing adverse events.
resultsAt three hours following drug delivery, measurements of heart rate, mean arterial pressure, respiratory rate, and blood gas parameters in Group A were more favorable than those in Group B (
conclusionIn agitated patients with TBI, dexmedetomidine was associated with improved sedative and analgesic effects, more stable sedation maintenance, reduced need for additional clinical interventions, and better preservation of respiratory and hemodynamic stability, as well as cerebral oxygen metabolic balance. Propofol, inadequate analgesia, and sedation fluctuations were independent risk factors for adverse events, and dexmedetomidine specifically reduced these risks with a higher safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.